Navigation Links
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
Date:11/25/2008

LAS VEGAS, Nov. 25 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT), announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease. The ACORD (Angiogenesis for the treatment of CORonary heart Disease) trial will include four randomized, double-blind, placebo-controlled doses in approximately 120 patients with severe coronary heart disease. Thirty sites are expected to participate.

CVBT's drug candidate (CVBT-141H) contains a human protein, Fibroblast Growth Factor-1 (FGF-1), that will be injected into patients' hearts with the intent to stimulate a healing process called angiogenesis. The drug will be targeted and delivered using the 3-D mapping NOGA(R) XP Cardiac Navigation system and the MyoStar injection catheter.

According to Daniel C. Montano, CVBT's CEO, "although it has taken longer than expected to reach this milestone, I am delighted that our Phase II heart trial is finally underway." Mr. Montano continued, "dosing the first patients is a major advancement in the development and verification of our drug."

Patients must be between 25 and 75 years of age with at least a three month history of chronic chest pain or discomfort triggered by physical exertion and must have severe coronary heart disease (a Canadian Cardiovascular Society (CCS) anginal classification III or IV). Patients must be receiving optimal medical therapy. Their treating cardiologist will have determined that they are generally not suitable for standard interventional therapy or bypass surgery.

To learn more about enrollment, patients or caregivers should contact clinical sites participating in the study directly. Active participating sites can be found by visiting http://www.cvbt.com.

About CVBT-141H'/>"/>

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trius Doses First Patient in Antibacterial Phase 2 Trial
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
4. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
7. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
8. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
9. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
10. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... -- Research and Markets has announced the addition ... Diarrhea, Mental Disorder) Market - Forecast to 2023" report ... report, the human microbiome market is segmented by application, disease, ... expected to be valued as $294 million in 2019 and ... the forecast period of 2019-2023. The market is driven by ...
(Date:9/19/2014)... -- Diplomat, the nation,s largest independent specialty pharmacy, has announced ... Board of Directors on September 15, 2014. Mr. Dreyer ... chair of the Audit Committee. Mr. ... and operating experience in the health care field.  Since ... officer, chief operating officer and secretary of Patient Safety ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3David Dreyer Appointed to Diplomat Board of Directors 2
... Professional Offers Patient Tips to Guard Against,Hospital Infections, ... Hospital,infections are among the top ten leading causes ... Centers for Disease Control. There,are countless stories about ... leave under much graver circumstances. As a,patient, knowing ...
... Findings Move Science Closer to Targeted, Improved Therapies , ... on Drug Abuse (NIDA), part of the National,Institutes of ... increase a person's ability to abstain from smoking. The,breakthrough ... Research Program and a team led by Dr. Jed ...
Cached Medicine Technology:Six Important Things to Know About Preventing Hospital Infections 2Six Important Things to Know About Preventing Hospital Infections 3NIDA Study Identifies Genes That Might Help Some People Abstain,from Smoking 2NIDA Study Identifies Genes That Might Help Some People Abstain,from Smoking 3
(Date:9/21/2014)... 21, 2014 "I want to help ... back but haven’t the money for chiropractors," said an ... have such a product for myself." , The Stretch ... stretch the thigh muscles and align the spine properly. ... relieves discomfort of pinched nerves. Compact and easy to ...
(Date:9/21/2014)... September 21, 2014 The Electronic ... and supports electronic medical records (EMR) and electronic ... federal healthcare legislation during the past five years ... during the five years to 2019. The 2009 ... Act established Medicare and Medicaid incentives to encourage ...
(Date:9/21/2014)... Best Cheap Hosting USA, one of the leading ... GreenGeeks are the best Reseller hosting suppliers in 2014. ... supplier. Actually, these companies have outperformed their competitors on ... can get the best web hosting at affordable rates,” ... the manager, reseller hosting is a very popular way ...
(Date:9/21/2014)... Originally approved by the Food ... (fluticasone propionate) is a synthetic ICS therapy with ... maintenance treatment of asthma prophylactically in children and ... Diskus and HFA, which received the FDA approval ... fluticasone propionate, can bind to glucocorticoid receptors with ...
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk decided to ... Recently, the company has unveiled its 2014 vintage ... wedding gowns, Angeldress.co.uk wants to make sure that all ... way. Its high quality vintage wedding outfits are now ... 62% off. , Online shopping is becoming more and ...
Breaking Medicine News(10 mins):Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2
... University of New York at the Buffalo School of Dental ... fibrinogen, a protein useful in blood clotting may increase the ... gums, those with gum disease carry certain gene variations linked ... , 79 people with gum ...
... In a landmark breakthrough, scientists have created mice with unusually ... also opening a possibility of helping people forget their distressing ... the molecular processes that govern memory and learning in the ... Technology in Zurich. , ...
... expands into Optical Coherence Tomography. This breakthrough has made many ... This has been developed by Dr. Brett Bouma an assistant ... tomography to gauge stent status.// , ... ultrasound and will allow cardiologists to view the status of ...
... on more than 1600 women reveals that parathyroid hormone (parathormone) increases ... them. The same hormone is also useful in regulating calcium levels ... new aspect of the hormone guarding against fractures has opened up ... brittle bone disease as it is also known as.// , ...
... May 24th issue of Nature reveals that the Obesity Hormone ... in more complex way than previously believed. This break through ... Obesity and many nutrition related disorders like anorexia nervosa. Dr. ... led the study. , ...
... actually repair itself by growing new cells after a heart ... York and Italy. Dr. Piero Anversa and colleagues of the ... muscle cells called myocytes continued to divide after a heart ... team examined the hearts of 13 people who died within ...
Cached Medicine News:
This large 1000 L tip makes pipetting fragile cells, genomic DNA, and viscous samples easy. Perfect for cell culture laboratories....
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
Conducting disposable filter-tips....
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
Medicine Products: